{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT04634539","nct_id":"NCT04634539","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04634539. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"For the dose-finding portion of this study, all subjects will receive a combination of L-glutamine, gemcitabine, and nab-paclitaxel which will be preceded by a 1-week (+/- 1 day) administration of L-glutamine. This 1-week administration of L-glutamine will facilitate measurement of baseline and post-glutamine monotherapy plasma metabolite levels prior to addition of gemcitabine and nab-paclitaxel. The combination therapy will be administered over 28-day cycles during the treatment period until disease progression, treatment intolerance, or withdrawal from the study. Patients are expected to be on treatment for 12 cycles.","label":"Gemcitabine + Nab-paclitaxel + L-glutamine","type":"EXPERIMENTAL"}],"collaborators":["Emmaus Medical, Inc."],"completion_date":{"date":"2025-06-17","type":"ACTUAL"},"conditions":["Advanced Pancreatic Adenocarcinoma","Pancreatic Cancer","Pancreatic Ductal Adenocarcinoma"],"enrollment":{"count":18,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":[],"type":"DRUG"},{"name":"L-glutamine","otherNames":["Endari"],"type":"DRUG"}],"last_update":"2025-08-06","lead_sponsor":"Jun Gong, MD","official_title":"IIT2020-02-Gong-GlutaPanc: Phase I Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer (GlutaPanc)","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2023-07-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Recommended phase II dose (RP2D) of combination gemcitabine, nab-paclitaxel, and L-glutamine in treatment-naive metastatic pancreatic cancer.","timeFrame":"4 weeks"}],"references":[{"citation":"Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S, Furuya H, Osipov A, Lorber J, Billet S, Morris A, Ten Hoeve-Scott J, Graeber T, Pandol SJ, Hendifar A, Bhowmick NA. L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial. Nat Cancer. 2026 Aug 31. doi: 10.1038/s43018-026-01225-z. Online ahead of print.","pmid":"42675216","type":"DERIVED"}],"start_date":{"date":"2021-05-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer","url":"https://clinicaltrials.gov/study/NCT04634539"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04634539"}